Increased expression of the APOB mRNA editing catalytic subunit-like enzyme, APOBEC3B, has also been observed in NSCLC patients receiving EGFR-targeted therapy [22]. This evidence concerns the gene APOBEC3B and non-small cell lung carcinoma.